[1] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
[2] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[3] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[4] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[5] |
YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo.
Risks of safety Qingkailing oral preparation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
|
[6] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[7] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[8] |
DU Ying, XIE Yanming, WANG Lianxin, GENG Hongjiao, LI Xiangjie.
Clinical characteristics and drug combination analysis of Lianhua Qingwen capsules (granules) in the real world
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 296-300.
|
[9] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[10] |
WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei.
Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
|
[11] |
HOU Tiantian, MA Sisi, WU Xiaobing, HUO Guitao, PAN Dongsheng, WANG Chao, XIA Yan, LIU Yi, ZHOU Xiaobing, LIU Guoqing, GENG Xingchao.
Toxicity of gene therapy drug AAV5-LPLS447X in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 19-26.
|
[12] |
HOU Tiantian, XIA Yan, PAN Dongsheng, HUO Guitao, MA Xuemei, LIU Ziyang, SUN Li, LIU Yi, YAN Jian'ao, WU Xiaobing, ZHOU Xiaobing, LIU Guoqing, GENG Xingchao.
Toxicity of gene therapy drug AAV5-LPLS447X (GC304) in cynomolgus monkeys
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 27-33.
|
[13] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[14] |
DONG Hanshuo, SUN Li, ZHAO Xiaoxiao, WANG Lianxin, YU Xiaokang, XIE Yanming.
Clinical characteristics and drug combination analysis of elemene injectable emulsion in the elderly in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 845-850.
|
[15] |
YANG Fan, MA Haiping, YOU Mengru, LIAO Sha, LIU Lan, ZHU Jun.
Applications of antiviral drugs in 456 patients with COVID-19
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 413-416.
|